Avanir Pharmaceuticals (AVNR) Reports In-Line Q2 EPS

Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q2 EPS of ($0.11), in-line with the analyst estimate of ($0.11). Revenue for the quarter came in at $10.1 million versus the consensus estimate of $10.29 million.

For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; raises guidance
• Elevance Health beats estimates but shares fall on margin concerns
• ServiceNow (NOW) PT Raised to $140 at Oppenheimer